Answers are grounded in this paper and cite their sources.
Retrospective study demonstrates effectiveness of rituximab in reducing relapses in children with IgAN-MCD, suggesting a viable treatment option.
IgA nephropathy with minimal change disease (IgAN-MCD) is a rare glomerulopathy combining features of both entities, typically presenting as steroid-sensitive nephrotic syndrome (NS) with frequent relapses. While rituximab (RTX) is commonly used in pediatric glomerular diseases, its efficacy in IgAN-MCD remains unclear. Our retrospective study evaluated the efficacy and safety of RTX in eight children with IgAN-MCD who remained steroid-dependent or frequently relapsed despite treatment with glucocorticoids and second-line immunosuppressants before RTX. Over a follow-up period of 12–41 months, RTX significantly reduced the annual relapse rate by 1.1 episodes per year, prolonged remission by 3.5 months, and extended the steroid-free interval by 7.4 months. Overall, 87.5% of patients successfully discontinued glucocorticoids, and 50% stopped immunosuppressants. Three patients relapsed at 9, 16, and 19 months, likely due to insufficient CD19+ B-cell monitoring and lack of consolidation dosing, yet all achieved sustained remission by the final follow-up. No serious RTX-related adverse events were observed. These findings suggest that RTX effectively reduces relapse, prolongs remission, and decreases dependence on steroids and immunosuppressants in pediatric IgAN-MCD, with a favorable safety profile for refractory cases.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: